Form 8-K Passage BIO, Inc. For: May 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Passage Bio terminates collaboration deal, exits office lease
May 27, 2026 4:19 PM EDTPassage Bio Inc. (NASDAQ: PASG) terminated its research collaboration agreement with Gemma Biotherapeutics Inc., providing written notice on May 21, 2026, according to a company statement.
The collaboration agreement, originally signed on July 31, 2024, involved Gemma conducting preclinical and Investigational New Drug-enabling work for Passage Bio's... More
